Skip to content
852-Overcoming T Cell Tolerance episode artwork

Apr 25, 2026 19 min

852-Overcoming T Cell Tolerance

from Paper Talk

This research article describes a novel "TCR turbocharging" pipeline designed to enhance the effectiveness of T cell receptors used in cancer immunotherapy. Scientists focused on a specific receptor, TCR156, which targets a prostate cancer antigen but naturally lacks the strength to eliminate tumors due to immune tolerance. By engineering specialized interactions called catch bonds, which strengthen under mechanical force, the researchers created variants like S32Mα that exhibit significantly higher potency. These modified T cells demonstrated a superior ability to shrink tumors in animal models without increasing the risk of dangerous off-target reactions. Ultimately, the study provides a biophysical blueprint for transforming weak, naturally occurring immune cells into powerful therapeutic tools for treating malignancies. References: Chen X, Mao Z, Kolawole E M, et al. Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering[J]. Science, 2026, 391(6791): eadx3162. 前往小宇宙评论区与主播互动

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

852-Overcoming T Cell Tolerance

0:00 19:28

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Paper Talk?

This episode is 19 minutes long.

When was this Paper Talk episode published?

This episode was published on April 25, 2026.

Can I download this Paper Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.